title: Classification of wounds at risk and their antimicrobial treatment with polihexanide: a practice-oriented expert recommendation.
abstract: Currently, there are no generally accepted definitions for wounds at risk of infection. In clinical practice, too many chronic wounds are regarded as being at risk of infection, and therefore many topical antimicrobials - in terms of frequency and duration of use - are applied to wounds. Based on expert discussion and current knowledge, a clinical assessment score was developed. The objective of this wounds at risk (W.A.R.) score is to allow decision-making on the indication for the use of antiseptics on the basis of polihexanide. The proposed clinical classification of W.A.R. shall facilitate the decision for wound antisepsis and allow an appropriate general treatment regimen with the focus on the prevention of wound infection. The W.A.R. score is based on a clinically oriented risk assessment using concrete patient circumstances. The indication for the use of antiseptics results from the addition of differently weighted risk causes, for which points are assigned. Antimicrobial treatment is justified in the case of 3 or more points.
authors.affiliation: Department of Dermatology, Universitätsklinikum Essen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Dissemond
authors.forename: O
authors.initials: O
authors.lastname: Assadian
authors.forename: V
authors.initials: V
authors.lastname: Gerber
authors.forename: A
authors.initials: A
authors.lastname: Kingsley
authors.forename: A
authors.initials: A
authors.lastname: Kramer
authors.forename: D J
authors.initials: DJ
authors.lastname: Leaper
authors.forename: G
authors.initials: G
authors.lastname: Mosti
authors.forename: A
authors.initials: A
authors.lastname: Piatkowski de Grzymala
authors.forename: G
authors.initials: G
authors.lastname: Riepe
authors.forename: A
authors.initials: A
authors.lastname: Risse
authors.forename: M
authors.initials: M
authors.lastname: Romanelli
authors.forename: R
authors.initials: R
authors.lastname: Strohal
authors.forename: J
authors.initials: J
authors.lastname: Traber
authors.forename: A
authors.initials: A
authors.lastname: Vasel-Biergans
authors.forename: T
authors.initials: T
authors.lastname: Wild
authors.forename: T
authors.initials: T
authors.lastname: Eberlein
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000276:immunology / Q000627:therapeutic use*; D001645:Biguanides / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007121:Immunocompetence; D016867:Immunocompromised Host; D018570:Risk Assessment; D012307:Risk Factors; D014946:Wound Infection / Q000382:microbiology / Q000517:prevention & control*; D014947:Wounds and Injuries / Q000145:classification* / Q000382:microbiology / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000891:Anti-Infective Agents, Local; D001645:Biguanides; C031233:polihexanide